PeerView Press Home Page
Before beginning, scroll to review all program information. To proceed, you must click the "Start This Activity" button.

Activity Description & Educational Objectives

In this activity, an expert in hematology/oncology discusses treatment of relapsed/refractory multiple myeloma.

Upon completion of this activity, participants should be better able to:

  • Identify barriers to therapeutic efficacy in the relapsed/refractory setting, including toxicity and treatment resistance
  • Recommend therapy for a patient with relapsed/refractory myeloma based on disease aggressiveness, treatment history, and other considerations
  • Develop salvage regimens in the myeloma setting designed to minimize toxicity and maximize efficacy
  • Summarize key findings on novel and/or emerging proteasome inhibitors, IMiDs, antibodies, and other targeted options in pretreated myeloma

Target Audience

This activity has been designed to meet the educational needs of hematologists, oncologists, and other clinicians involved in the treatment of patients with relapsed/refractory multiple myeloma.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Internet
Release and Expiration Dates: May 16, 2014 - May 15, 2015
Time to Complete: 30 minutes

Faculty & Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Course Director and Interviewee

Robert Z. Orlowski, MD, PhD
Professor of Medicine
Director, Myeloma Section
Departments of Lymphoma/Myeloma and Experimental Therapeutics
Division of Cancer Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Robert Z. Orlowski, MD, PhD, has a financial interest/relationship or affiliation in the form of:

Consultant for Abbott Laboratories; Array BioPharma Inc.; Bristol-Myers Squibb; Celgene Corporation; Genentech, Inc.; Millennium Pharmaceuticals, Inc.; and Onyx Pharmaceuticals, Inc.

Grant/Research Support from Bristol-Myers Squibb; Celgene Corporation; Millennium Pharmaceuticals, Inc.; and Onyx Pharmaceuticals, Inc.

Medical Director

Carmine DeLuca
PVI, PeerView Institute for Medical Education

Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.

Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.

Sponsorship, Credit & Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and PVI, PeerView Institute for Medical Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.‚Äč

The Penn State College of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or Reference course # G5508-14-T.

This CME activity is jointly provided by Penn State College of Medicine and PVI, PeerView Institute for Medical Education.

This activity is supported by an educational grant from Celgene Corporation.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.


We do not recognize you as a registered member.
Please log in by selecting your specialty below:

I have read the required activity information
Start This Activity